Join
Live feed
·
PRReleasevia Quantisnow
AIM ImmunoTech Inc. logo

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

ByQuantisnow·Wall Street's wire, on your screen.
AIM· AIM ImmunoTech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AIM (AIM ImmunoTech Inc.) and more on Quantisnow.